For most of the twentieth century, inflammation was understood as a process that simply faded away once the initiating stimulus was removed — a passive dissipation. That assumption collapsed in the early 2000s when Charles Serhan’s laboratory at Harvard Medical School discovered that resolution of inflammation is an active, biochemically programmed process driven by a distinct family of lipid mediators derived from omega-3 fatty acids. These molecules — resolvins, protectins, and maresins — don’t suppress inflammation. They end it.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a class of endogenous lipid signaling molecules enzymatically synthesized from polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with some derived from arachidonic acid (lipoxins) and docosapentaenoic acid (DPA). They were first identified by Serhan and colleagues, who demonstrated that resolution of acute inflammation is not the absence of pro-inflammatory signaling but the presence of a parallel, actively orchestrated program.[1]
The major SPM families include resolvins (E-series from EPA, D-series from DHA), protectins (from DHA, including protectin D1/neuroprotectin D1), maresins (macrophage mediators in resolving inflammation, from DHA), and lipoxins (from arachidonic acid). Each is produced through sequential lipoxygenase and sometimes cyclooxygenase reactions and acts on specific G-protein-coupled receptors at picomolar to nanomolar concentrations.[1,2]
How SPMs Work
Biosynthesis from Omega-3 Substrates: EPA and DHA are not merely “anti-inflammatory” through membrane incorporation. They serve as enzymatic substrates. 15-lipoxygenase and 5-lipoxygenase act sequentially on DHA to generate D-series resolvins (RvD1–RvD6) and on EPA to generate E-series resolvins (RvE1–RvE3). Maresins are produced by macrophage 12-lipoxygenase acting on DHA, while protectins arise via 15-lipoxygenase-mediated epoxidation and hydrolysis.[2]
Receptor-Mediated Signaling: SPMs act through specific GPCRs. RvE1 binds ChemR23 (ERV) and antagonizes BLT1; RvD1 binds ALX/FPR2 and GPR32; maresin 1 acts through LGR6. These receptors are expressed on neutrophils, macrophages, dendritic cells, and tissue-resident cells. Engagement triggers a programmed shift from a pro-inflammatory to a pro-resolving phenotype.[2,3]
Cellular Effects on Neutrophils and Macrophages: SPMs do not block leukocyte recruitment broadly. Instead, they halt further neutrophil infiltration once an inflammatory site has been adequately staffed, accelerate neutrophil apoptosis, and — critically — stimulate macrophage efferocytosis (the engulfment of apoptotic neutrophils). They also drive macrophage polarization from M1 (pro-inflammatory) toward M2 (pro-resolving and tissue-reparative) phenotypes.[3]
Class Switching of Lipid Mediators: During the resolution phase of acute inflammation, there is an enzymatic “class switch” in which leukocytes shift from producing pro-inflammatory leukotrienes and prostaglandins to producing lipoxins and resolvins. This switch is itself triggered by prostaglandins E2 and D2 — meaning that early pro-inflammatory mediators encode the instructions for their own termination.[1]
Clinical Evidence
Chronic Inflammatory Disease: Reduced SPM biosynthesis has been documented in patients with chronic inflammatory conditions. Lipid mediator profiling studies have shown altered resolvin and protectin levels in peripheral blood of patients with rheumatoid arthritis, asthma, cardiovascular disease, and chronic periodontitis, suggesting that failed resolution — not excess initiation — may underlie chronic inflammation.[3]
Cardiovascular Disease: The REDUCE-IT trial demonstrated that high-dose icosapent ethyl (purified EPA) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides. While the trial did not measure SPMs directly, the magnitude of benefit — disproportionate to triglyceride lowering — has prompted investigation into whether enhanced E-series resolvin production contributes to the effect.[4]
Infection Resolution: SPMs do not immunosuppress. In animal models of bacterial pneumonia and sepsis, resolvin treatment enhances bacterial clearance while reducing collateral tissue damage — a profile distinct from glucocorticoids or NSAIDs, which can impair host defense. This “resolution pharmacology” represents a fundamentally different therapeutic strategy.[2]
Neuroinflammation and Pain: Resolvins and neuroprotectin D1 have been shown to attenuate inflammatory and neuropathic pain in preclinical models at doses orders of magnitude lower than conventional analgesics, acting in part through TRPV1 modulation and reduced spinal microglial activation.[5]
Why Omega-3 Supplementation Doesn’t Always Translate
Trials of omega-3 supplementation have produced mixed results — some showing cardiovascular benefit, others null. The SPM framework offers a partial explanation. EPA and DHA must be enzymatically processed by lipoxygenases to generate active resolvins and protectins. Individual variation in lipoxygenase expression and activity, concurrent NSAID use (which can inhibit certain biosynthetic steps), and oxidative stress that diverts substrate all influence whether ingested omega-3 actually translates into circulating SPMs.[2,3]
Direct measurement of SPM levels — rather than EPA/DHA intake — may be a more relevant biomarker. Some commercial preparations now contain SPM intermediates (17-HDHA, 18-HEPE, 14-HDHA) rather than parent fatty acids, on the rationale that these mono-hydroxylated precursors are closer to the bioactive end-products.
Safety Profile
Endogenous SPMs operate at picomolar to low nanomolar concentrations and are rapidly metabolized — their half-lives are measured in minutes. This contrasts with NSAIDs and glucocorticoids, which act systemically for hours and broadly suppress inflammation. In animal studies, even supraphysiologic SPM doses have not produced the immunosuppression, GI toxicity, or cardiovascular harm associated with chronic NSAID use.[2]
Omega-3 supplementation itself has a well-characterized safety profile in human trials, with the main concerns being mild GI upset, fishy aftertaste, and a theoretical bleeding risk that has not materialized in large cardiovascular outcome trials, including REDUCE-IT.[4] Direct SPM administration in humans remains largely investigational; commercial SPM-precursor products are regulated as supplements and lack the rigorous dose-response data of pharmaceutical agents.
SPMs vs Conventional Anti-Inflammatory Approaches
NSAIDs: Cyclooxygenase inhibitors reduce prostaglandin synthesis but also block the prostaglandin-driven class switch that initiates resolution. Aspirin is a partial exception — it acetylates COX-2 to produce 15R-epimers of lipoxins and resolvins (“aspirin-triggered” SPMs), which may contribute to aspirin’s distinctive cardioprotective effects.[1]
Glucocorticoids: Steroids broadly suppress immune activation, including pathways needed for pathogen clearance and tissue repair. SPMs, by contrast, accelerate clearance and repair without immunosuppression.[3]
Biologic Cytokine Blockade: TNF-α and IL-6 inhibitors are highly effective in autoimmune disease but increase infection risk and do not actively promote resolution. Combining cytokine blockade with resolution-enhancing strategies is an active area of investigation.
Conceptual Shift: The SPM literature reframes chronic inflammation as a disease of failed resolution rather than excessive initiation. This is not semantic — it implies that therapies designed to enhance resolution may succeed where suppression has plateaued, particularly in conditions characterized by smoldering, low-grade inflammation such as atherosclerosis, neurodegeneration, and metabolic disease.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Chiang N, Serhan CN. “Specialized pro-resolving mediator network: an update on production and actions.” Essays in Biochemistry. 2020;64(3):443-462.
- Bhatt DL, et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” New England Journal of Medicine. 2019;380(1):11-22.
- Ji RR, Xu ZZ, Strichartz G, Serhan CN. “Emerging roles of resolvins in the resolution of inflammation and pain.” Trends in Neurosciences. 2011;34(11):599-609.
